Login to Your Account



Clinic Roundup


Wednesday, May 8, 2013
• Opsona Therapeutics Ltd., of Dublin, Ireland, said it started a Phase II trial of OPN-305, a humanized IgG4 monoclonal antibody against Toll-like receptor 2, in renal transplant patients at high risk of delayed graft function (DGF).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription